European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- __hot__ (2025-2027)

The monograph references strict testing methods to ensure that the variance between tablets is statistically insignificant. This is where the "mass variation" test meets the "content uniformity" test. If a tablet contains a tiny amount of potent API (like a hormone or an opioid), weighing the tablet isn't enough; chemists must assay the content of individual units. 0478 dictates when to use which method, ensuring that a patient never receives a "super-potent" or "sub-potent" dose.

Do you need a comparison between standards? Are you interested in the latest 11th Edition updates ? Share public link

: Modified-release formulations engineered to resist gastric fluid and release the API within the intestinal tract. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

The monograph outlines several mandatory tests that assess both physical integrity and chemical uniformity: European Pharmacopoeia - Background and Mission

The heart of Monograph 0478 lies in its mandated quality control tests. These tests are designed to guarantee that every batch of tablets meets predefined criteria for identity, purity, and performance. The monograph references strict testing methods to ensure

Tablets must be stored in airtight containers to prevent moisture uptake, which can trigger premature disintegration (especially in effervescent types) or chemical degradation of the API.

The monograph demands that tablets be "sufficiently hard to withstand handling." But it also introduces the concept of (often referenced in conjunction with the monograph). Friability is the tendency of a tablet to crumble. If a tablet is too hard, it won't dissolve; if it's too soft, it turns to dust in the bottle. Monograph 0478 ensures that the definition of "quality" includes structural integrity, preventing patients from receiving a partial dose due to chipped or broken pills. 0478 dictates when to use which method, ensuring

This is arguably the most critical safety and efficacy test. It ensures that each tablet in a batch contains the active substance within a narrow range (typically 85–115% of the label claim). The test is performed according to General Chapter 2.9.40, using either content uniformity (individual assay of 10 tablets) or mass variation (weighing tablets for potent drugs). Failure here indicates poor manufacturing mixing or compression, leading to underdosing (ineffectiveness) or overdosing (toxicity).